Crossmark

Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies

Crossref DOI link: https://doi.org/10.1016/j.nefro.2024.06.007

Published Print: 2024-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Suciangto, William

Rasyid, Haerani

Vicente, Anastasya Angelica

Suciangto, Winny
License Information

Text and Data Mining valid from 2024-11-01

Text and Data Mining valid from 2024-11-01

Version of Record valid from 2024-06-13
More Information

This article is maintained by: Elsevier

Article Title: Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies

Journal Title: Nefrología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nefro.2024.06.007

Content Type: article

Copyright: © 2024 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below